News and Updates

The British Liver Trust want to keep Healthcare Professionals  involved in liver care up to date with news and developments from the Trust and the wider hepatology industry.

HCP Newsletter

The British Liver Trust sends a quarterly healthcare professional update, containing news, articles and links of specific interest to professionals in clinical practice. You can sign up to receive these emails:


 New British Liver Trust Patient Leaflet

Thinking ahead: Planning for your future with advanced liver disease

The publication has been designed to help patients with advanced chronic liver disease to talk about how the condition affects their lives, and to think about their wishes for the future. It will help patients discuss how they would like future care to progress, and also contains information about end of life care in a separate section.


If you have a copy of our bound volume of patient information you will automatically have been posted a copy of the new leaflet in order to update your binder here:

New treatments approved by NICE

 A life-extending treatment for some adults with advanced liver cancer has been recommended for use on the NHS by NICE after a rapid review of guidance published earlier in the year.

The drug regorafenib (also called Stivarga and made by Bayer) can now be offered to people with advanced liver cancer if their liver is working well but the diseased area cannot be surgically treated and if they have already taken the life-extending medicine sorafenib.

People must also have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, which means they are fully active and able to carry out normal activities of daily life without restriction, or they are restricted in physically strenuous activity but able to carry out work of a light or sedentary nature.  Read more:

NICE recommends use of the alfapump® for the treatment of refractory ascites caused by cirrhosis under special arrangements.

The National Institute for Health and Care Excellence (NICE) has published updated Interventional Procedures Guidance (IPG) supporting the use of the alfapump® for the treatment of refractory ascites caused by cirrhosis.

NICE) has approved the liver cancer drug Lenvima® (lenvatinib) for routine use in the NHS in England and Wales. This is a new first-line treatment for patients with advanced Hepatocellular carcinoma (HCC), which is the most common type of liver cancer.

For further information see

Public Health England and NHS England are working to find thousands of people living with hep C, offering them new treatments that, in most cases, cure the illness.

Public Health England (PHE) and NHS England have launched a national exercise to identify and treat patients who have been previously diagnosed with hepatitis C.

In recent years new, potentially curative treatments have been developed for hepatitis C, but tens of thousands of people who were diagnosed in the past may not have accessed them.

A new report, the first of its kind, by PHE shows more than 24,500 people in England have accessed new hepatitis C treatments in the last 3 years.

Public Health England has also produced new information for general practitioners and patients to support them in the quest to find those who have been infected.

NCATS announces two new funding opportunities to support clinical trial readiness for rare diseases

NCATS has announced two new funding opportunities to support clinical trial readiness for rare diseases—an R03 and an R21. These initiatives are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.

Transforming the landscape of liver disease in the UK – new Lancet report

Gathering momentum for the way ahead: the fifth report of the Lancet Standing Commission on Liver Disease in the UK, showcases the progress made and provides a substantial addition to European and global health data on the extent of the liver disease burden.

Examples of the progress being made include

  • The British Liver Trust and Royal College of General Practitioners renewed commitment to driving forward screening programmes so that high-risk patients are identified much earlier in primary care.
  • Innovative programmes, such as the Nottingham Scarred Liver Project, are providing resources for general practitioners to identify patients with hazardous alcohol use for counselling interventions and transient elastography liver function tests.
  • The widespread availability of new curative antiviral treatments for hepatitis C virus in the UK has transformed care, bringing the WHO target for eliminating hepatitis C virus by 20303 within reach.
  • The UK waiting list for liver transplants in 2017–18 reduced to almost half of that in 2014–15.
  • In Scotland, a minimum unit price for alcohol was introduced in May, 2018.

British Liver Trust Patient Leaflets – Feedback Request

Our latest updated publications have been sent out to HCPs who have registered for our patient information binder. We would like to feedback to our funders on the impact and use of the binders in clinical settings. If you would be able to provide feedback on how you are using this resource to support patients, please email

Love Your Liver Roadshow – London 2019

The British Liver Trust will stage the first roadshow of 2019 in the final week of March. Our mobile screening unit will tour 4 locations in London, offering members of the public the chance to check their liver health. For more information, and to see dates as they are confirmed, please sign up for our general newsletter or visit: Love Your Liver events 

If you would like to register to support the Roadshow as a healthcare professional when it visits your area please email us at the address below.